View Cart  

FDA Nixes Cornerstone Low-Sodium Drug, Asks for More Clinical Info

A A
The FDA has shot down Cornerstone Therapeutics’ low-sodium drug lixivaptan for both its proposed indications.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00